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Abstract
Background: This study compares the costs and effects of a regimen with ritonavir-boosted tipranavir (TPV/r) to a
physician-selected genotypically-defined standard-of-care comparator protease inhibitor regimen boosted with ritonavir
(CPI/r) in HIV infected patients that were previously exposed to antiretroviral therapy in the Netherlands.
Methods: We compared the projected lifetime costs and effects of two theoretical groups of 1000 patients, one
receiving a standard of care regimen with TPV/r as a component and the other receiving a standard of care regimen with
CPI/r. A 3-stage Markov model was formulated to represent three different consecutive HAART regimens. The model
uses 12 health states based on viral load and CD4+ count to simulate disease progression. The transition probabilities
for the Markov model were derived from a United States cohort of treatment experienced HIV patients. Furthermore,
the study design was based on 48-week data from the RESIST-2 clinical trial and local Dutch costing data. Cost and health
effects were discounted at 4% and 1.5% respectively according to the Dutch guideline. The analysis was conducted from
the Dutch healthcare perspective using 2006 unit cost prices.
Results: Our model projects an accumulated discounted cost to the Dutch healthcare system per patient receiving the
TPV/r regimen of €167,200 compared to €145,400 for the CPI/r regimen. This results in an incremental cost of €21,800
per patient. The accumulated discounted effect is 7.43 life years or 6.31 quality adjusted life years (QALYs) per patient
receiving TPV/r, compared to 6.91 life years or 5.80 QALYs per patient receiving CPI/r. This translates into an
incremental effect of TPV/r over CPI/r of 0.52 life years gained (LYG) or 0.51 QALYs gained. The corresponding
incremental cost effectiveness ratios (iCERs) are €41,600 per LYG and €42,500 per QALY.
Conclusion: We estimated the iCER for TPV/r compared to CPI/r at approximately €40,000 in treatment experienced
HIV-1 infected patients in the Netherlands. This ratio may well be in range of what is acceptable and warrants
reimbursement for new drug treatments in the Netherlands, in particular in therapeutic areas as end-stage oncology and
HIV and other last-resort health-care interventions.
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Background
The human immunodeficiency virus (HIV) that causes
acquired immunodeficiency syndrome (AIDS) confronts
us with a pandemic that is one of the biggest health prob-
lems in the world today. The Netherlands is known as a
low-prevalence country, where the HIV epidemic is
mostly confined within risk-groups. In recent years how-
ever, the majority of new HIV infections have occurred in
patients of the general population without obvious risk-
factors. Heisterkamp et al. [1] estimated the number of
predominantly HIV-1 infected individuals (regardless of
stage of disease) at 8,377 by the end of 2004, in the Neth-
erlands.
The introduction of highly active antiretroviral therapy
(HAART) has been one of the greatest therapeutic
advances in slowing disease progression of HIV since the
introduction of zidovudine in 1987. HAART consists of a
combination of nucleoside or nucleotide reverse tran-
scriptase inhibitors (NRTIs), non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), protease inhibitors (PIs)
and/or a fusion inhibitor, acting at different stages of the
replication cycle of the virus [2]. These combinations of
therapeutics succeed in long-term suppression of viral rep-
lication and have led to reduced mortality, improved
quality of life and a reduction in hospitalization rates and
opportunistic infections [3,4]. However, treatment failure
is still a relatively common problem in patients with HIV-
1 infection using combination antiretroviral therapy [5].
Contributing factors to treatment failure include poor tol-
erability, low adherence due to demanding drug regimens
and emergence of viral resistance [6,7]. Viral resistance
limits the number of therapeutic options available and
this effect is amplified when the virus develops cross-
resistance. Several studies from the international literature
indicate a frequent transmission of drug-resistant strains
[8]. In the Netherlands drug-resistant mutations are
reported in 10–30% of primary HIV-1 infections [9]. The
non-peptidic PI tipranavir (Aptivus®, Boehringer Ingel-
heim) co-administrated with a low dose of ritonavir (TPV/
r) provides an additional treatment option for highly
treatment-experienced HIV-1 infected patients where the
virus developed resistance during the course of previous
treatments. TPV/r suppresses viral replication of HIV-1, in
particular in isolates that are highly resistant to multiple
PIs [10,11].
Two randomized open-label phase III clinical trials,
RESIST-1 (Randomized Evaluation of Strategic Interven-
tion in multidrug reSistant patients with Tipranavir) and
RESIST-2, have demonstrated that patients treated with
TPV/r were twice as likely to achieve a viral load of less
than 50 copies per mL compared to investigator-selected
genotypically-defined ritonavir-boosted standard-of-care
comparator protease inhibitor (CPI/r) therapy at week 48
[12-14]. TPV/r was approved by EMEA and FDA in 2005
for use in highly treatment-experienced HIV-1 infected
patients [15].
Economic considerations are of increasing importance for
the reimbursement of new therapeutics. In a number of
countries (for instance, the Netherlands, United King-
dom, Australia and others), economics evaluations of
pharmaceuticals are required for decisions on the reim-
bursement of such new pharmaceuticals. Several cost-
effectiveness studies have been conducted comparing dif-
ferent antiretroviral combinations for HIV. However, in a
recent review over 1994–2004 Harling et al. reported that
the majority of these studies compare general regimen
types (mono, duo and triple HAART therapy) instead of
specific therapeutics or combinations of brands [2]. Only
a small number of studies compare one antiretroviral to
another within the context of HAART. One reason why
these evaluations are not frequent might be the difficult
task of modeling the complexity of multiple sequential
HAART regimes with different components. In this study
we have attempted to model this complexity based on
clinical trial data and plausible assumptions.
We compare the projected lifetime costs and effects in the
Netherlands of a cohort receiving TPV/r as compared to
CPI/r, both administered with an optimized background
regimen including at least 2 non-PI antiretrovirals (NRTIs,
NNRTIs or enfuvirtide).
Methods
Study design
To assess the life-time costs and effects of a TPV/r based
regimen compared to CPI/r, we used two theoretical
groups of 1000 HIV-1 infected patients in the Nether-
lands. One group was assumed to receive a regimen con-
taining TPV/r and the other a CPI/r-containing regimen.
All patients had previously been exposed to antiretroviral
regimens. A 3-stage Markov model was formulated to sim-
ulate the costs and effects during the lifetime of this treat-
ment experienced group of patients. A similar model was
previously applied to evaluate the cost-effectiveness of
lopinavir/ritonavir versus nelfinavir [16]. A diagram of the
model is shown in figure 1. The three stages represent
three different consecutive HAART regimens. Patients
transit to a next stage if their HAART regimen fails. Treat-
ment failure is determined on the patients' health state.
The model uses 12 health states based on viral load and
CD4+ count to simulate disease progression (table 1). We
use a Markov cycle of three months, corresponding to the
average time between patients' visits and the associated
analysis of markers for disease progression (CD4+ and
viral load parameters). The model runs until 90% of the
patients have died ("have entered the absorbing death
stage in the Markov model"). The analysis was conductedCost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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Diagram of the Markov model Figure 1
Diagram of the Markov model. The model consists of three stages representing three different consecutive therapy regi-
mens. All patients start in stage 1 and are assigned an initial health state based on the population of RESIST-2 at the start of the 
trial. During the first four cycles of the model patients' transitions to other health states and the death stage are identical to 
those observed in the RESIST-2 trial. After this trial-period, the patients' health state transitions are controlled by transition 
matrices based on observational data. The main trend over time is towards a less favorable health state indicated by the larger 
arrow pointing to the right. When patients reach health state 9–12 (treatment failure), they are moved to stage 2 through 
intermediate period 1. Patients remain in this intermediate period for 1 cycle where they transit to a more favorable health 
state controlled by improvement matrix 1, represented by the arrow pointing to the left. Patients move from stage 2 to 3 fol-
lowing the same pattern. TPV/r: tipranavir with ritonavir. CPI/r: comparator protease inhibitor with ritonavir. HAART: highly 
active antiretroviral therapy.Cost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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from a Dutch healthcare perspective, implying that only
direct medical costs were taken into account and indirect
costs due to production losses were excluded. The analysis
meets the most recent Dutch guidelines for pharmacoeco-
nomic research, implying that both costs and effects were
discounted at 4% and 1.5%, respectively [17]. All costs
were measured in Euros using 2006 price levels.
Details on the model
Model transitions
Patients transit to a next model stage if their HAART regi-
men fails. This is determined by the patient's health state.
Patients may transit both to more and less favorable
health states. However, the main trend is progression to a
less favorable health state. During all three model stages,
if a patient reaches one of the treatment failure health
states (9, 10, 11 and 12), the patient moves to the next
Markov stage. Treatment failure is exactly defined as
reaching a detectable viral load and a CD4+ count of <=
200. A patient moves to the next Markov stage through an
intermediate period of improvement where the patient
remains one Markov cycle. In this intermediate period,
patients progress to a more favorable health state.
As mentioned above, the analysis was conducted on a the-
oretical cohort provided with two alternative treatment
regimens. The cohort was comparable to the study partic-
ipants in the RESIST-2 trial with respect to viral load and
CD4+ count (see appendix for a brief description of the
trial [2]). In particular, all patients start in model stage 1
and are assigned a starting health state reflecting the viral
load and CD4+ counts of the population of RESIST-2 at
the start of the trial. During the initial 4 cycles the patients
follow transitions to other health states and the death
stage as observed during the first 48-week of the RESIST-2
trial, based on the patient's last viral load measurement
and the average of the CD4+ measurements of each 3-
month period. Patients in both arms of the RESIST-2 trial
that dropped out were considered as patients failing on
treatment and progressed to the second stage of the model
(causes for dropping out were among others 'no con-
firmed 1 log drop in viral load from baseline', 'virological
failure', and 'treatment discontinuation due to adverse
events'). Since data from the RESIST-2 trial was available
for this analysis up to 48-weeks, patient transitions after
this period were modeled using transition matrices that
were derived from a large observational cohort of 1546
HAART-experienced patients in the United States [18] rep-
resenting the quarterly progression rates observed for
patients that have spent at least 6 months on HAART.
These matrices contain the probability of progression or
regression of the patient to the other health states and to
the death stage. The improvement in intermediate periods
1 and 2 is governed by improvement matrices 1 and 2,
which were also derived from the aforementioned obser-
vational cohort [18]. These two improvement matrices of
the intermediate periods represent the improvement in
CD4+ cell count and suppression in viral load that occur
when a failing patient is switched to a new HAART regi-
men; i.e. a proportion of patients is boosted into a more
favorable health state. Improvement matrix 1 of interme-
diate period 1 reflects the immediate response to a new
HAART regimen: 70% of the patients were assumed to
have an increase of 50 CD4 cells/µl and 20% were
assumed to achieve an undetectable viral load. The
remaining 10% were unchanged. The improvement
matrix 2 of intermediate period 2 reflects the immediate
response to a salvage HAART regimen: 30% of the patients
Table 1: Health states with associated risks of AIDS events and quality of life weights
Heath State CD4+ count1 Viral load2 AIDS events3 [18] Quality of Life weight [19]
1 >500 Undetectable 1.71 0.954
2 >500 Detectable 2.18 0.938
3 351–500 Undetectable 1.71 0.934
4 351–500 Detectable 2.18 0.931
5 201–350 Undetectable 2.84 0.929
6 201–350 <10,000 3.31 0.931
7 201–350 =>10,000 4.25 0.933
8 50–200 Undetectable 5.11 0.863
9 50–200 <10,000 5.58 0.865
10 50–200 10,000–100,000 9.79 0.826
11 50–200 >100,000 14.47 0.876
12 <50 Any viral load 17.87 0.781
The 12 health states defined by CD4+ counts and viral load. Also shown are the associated risks of AIDS events and quality of life (QOL) weights 
for each health state.
1 Number of CD4+ cells per micro liter
2 RNA copies/mL (as measured by the Roche Amplicor HIV-1 Monitor)
3 Number of events per 100 patients over a 3-month periodCost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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were assumed to have an average increase of 30 CD4 cells/
µl and 10% of patients were assumed to achieve an unde-
tectable viral load. The remaining 60% were unchanged.
Therapy regimens
In stage 1 of the model one group receives TPV/r and the
other CPI/r. The different CPIs used – taken from the
RESIST-2-trial – are shown in table 2. TPV/r or CPI/r were
part of at least a triple therapy regimen consisting of dif-
ferent antiretrovirals, hereafter called the background reg-
imen. The components of the background regimen used –
also taken from the RESIST-2-trial – are listed in table 3.
In stage 2 patients receive a new HAART regimen. This reg-
imen consists of 2 of the PIs listed in table 2 combined
with lamvudine and stavudine. In stage 3 all patients
receive a salvage regimen. Various salvage regimens can be
considered. For costing, we considered a regimen that is
similar to the previous HAART regimen but with a dou-
bled dose of stavudine.
AIDS events and quality of life
Each health state corresponds to an associated risk of an
AIDS event (table 1). For each health state the risk of a
new AIDS event within a 3-month period was derived
from the observational cohort [18]. It was assumed that
only one type of event can occur to the same patient in
each cycle. Additionally, each health state has an associ-
ated quality of life (QOL) weight. These were derived
from the analysis of data from about 21,000 clinical trial
HIV patients assessed with the EuroQol instrument [19].
Each EuroQol-measurement within 30 days of a viral load
measurement and CD4+ cell count was classified into one
of the 12 health states. The average quality weight per
health state was subsequently calculated. Next, the model
was run for both the TPV/r and CPI/r groups and life years
were counted. The difference between both arms gave the
life years gained (LYG). Weighting the life years with the
respective quality-of-life weights gave the gains in quality
adjusted life years (QALYs).
Costs
In the first model stage, the costs of the PI regimens TPV/
r and CPI/r differ while the cost of the background antiret-
rovirals in stage 1 are the same in both groups. For stages
2 and 3, the regimen and the associated costs do not differ
between groups. The regimen costs of therapy in each
model stage are shown in table 2. These regimen costs are
the weighted average of the daily costs of individual regi-
men components, shown in table 3, based on unit costs
[20] and utilization in RESIST-2 (unpublished data). The
costs of HAART regimens were varied in sensitivity analy-
sis.
During all model stages and in both treatment groups the
same assumptions were used on costs and resource use of
HIV care. Patients were assumed to routinely visit the
clinic every three months corresponding to the average
time between patients' visits in the Netherlands. The costs
of these visits were assumed at €351, including a CD4+
cell count (€38) and viral load measurement (€209).
Additional costs of switching to a different antiretroviral
regimen were also assumed at €351. The extra costs of
changes in HAART regimen due to toxicities and the treat-
ment of toxicities were not included in the model.
The resource utilization and associated costs for AIDS
events (22 most common opportunistic infections and
other HIV events) were based on data from the University
Medical Centre Groningen (UMCG). The weighted aver-
age cost of the different types of AIDS events was esti-
mated at €8,264, using a bottom-up approach using
resource use data from the UMCG of the different types of
Table 3: Daily cost of regimen components
Protease inhibitor Daily costs (€)
tipranavir/ritonavir 28.00
Comparator protease inhibitor
lopinavir/ritonavir 14.54
amprenavir 15.21
Indinavir 8.93
Saquinavir 8.58
Background antiretroviral
Abacavir 9.54
Didanosine 6.96
Efavirenz 8.68
Emtricitabine 6.49
Enfuvirtide 25.27
Lamivudine 6.20
Nevirapine 7.79
Stavudine 5.38
Tenofovir 11.70
Zidovudine 8.04
Daily cost (Euro price level 2006) in the Netherlands of tipranavir, 
comparator protease inhibitors and antiretroviral background 
regimen components in the RESIST-2 trial (source: Z-index Nov. 
2006) [20].
Table 2: Daily cost per regimen
Regimen Daily cost (€)
Stage 1 – TPV/r + background antiretrovirals 71.70
Stage 1 – CPI/r + background antiretrovirals 55.74
Stage 2 – New HAART regimen 44.04
Stage 3 – Salvage HAART regimen 51.22
Daily cost (Euro price level 2006) per regimen in the Netherlands
TPV/r: tipranavir with ritonavir
CPI/r: comparator protease inhibitor with ritonavir
HAART: highly active antiretroviral therapyCost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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AIDS events and their relative occurrence, shown in table
4. This weighted average was adjusted to take into account
that for a number of AIDS event types no reliable cost data
was available from the UMCG databases due to the rela-
tively small number of HIV patients (N = 400). In partic-
ular, economic data was gathered for resource use
concerning AIDS events and for corresponding unit costs.
Initially, for all HIV-positive patients in the UMCG that
experienced one or more of such events in the years 2001
to 2004 direct medical resource use data was extracted
from the UMCG databases, 2 weeks before up to 5 weeks
after the registered date of the HIV-related event. Next, this
resource use was manually verified and corrected by a
research nurse using the electronic and paper patient med-
ical dossiers (permit of the Hospital Ethical Committee
was acquired). Incomplete patient files were excluded,
resulting in 36 successfully analyzed AIDS events.
Resource use was valued using the Dutch guidelines on
pharmacoeconomic research [17] where possible. In case
costing data was missing, we used reimbursement prices
using Dutch tariffs [21].
Sensitivity analysis
We assessed the uncertainty in the model parameters
through univariate sensitivity analysis. All cost parameters
were varied in the univariate sensitivity analysis over a
range of 75% to 125% of the base-case parameter value
and the impact on the iCER per QALY was presented in a
tornado diagram. The impact of the AIDS event rates were
investigated by multiplying these rates by 0.75 and 1.25.
Additionally, the discount rates were evaluated at values
of 0% and 5%. To assess the impact of a slower or faster
disease progression (that is reflected in the transition
probabilities of the transition matrices), we varied the
probability for each health state of a patient staying in that
particular health state by 5%. Simultaneously, the proba-
bility of transiting to the other health states is proportion-
ately increased or decreased. Utility weights were not
included in the sensitivity analysis.
Results
Base-case results
The lifetime accumulated cost to the healthcare system per
patient receiving the TPV/r regimen is estimated to be
€167,200 compared to €145,400 for a patient receiving
the CPI/r regimen. This results in an incremental cost per
patient of €21,800 (including lifetime savings of €167 per
patient due to the reduction in AIDS events). The accumu-
lated effect is 7.43 life years or 6.31 QALYs per patient
receiving TPV/r, compared to 6.91 life years or 5.80
QALYs per patient receiving CPI/r. This translates into an
incremental effect per patient receiving TPV/r compared
to CPI/r of 0.52 LYG or 0.51 QALYs gained per person.
The equivalent incremental cost effectiveness ratios
(iCERs) are €41,600 per LYG and €42,500 per QALY.
Sensitivity analysis
The results of the univariate sensitivity analysis on cost
parameters are presented in figure 2. This tornado dia-
gram ranks the cost parameters based on the magnitude of
their impact on the iCER per QALY. The diagram shows
clearly that the regimen costs of both arms have the high-
est impact on the model outcome. For the remaining cost
parameters, the model proved to be robust to changes.
Multiplying all AIDS event rates simultaneously by 0.75
and 1.25 had a relatively low impact on the iCER of
€42,800 and €42,200 per QALY, respectively. Addition-
ally, the discount rates were evaluated at 0% and 5%. This
Table 4: Occurrence and estimated cost of AIDS events
AIDS event Relative occurrence (%) Number observed in UMCG (N) Estimated Cost (€)
Candidiasis, oral or systemic 9.0 7 5,642
Herpes simplex 0.3 5 6,615
Kaposi sarcoma, cutaneous 3.8 1 1,972
Lymphoma 3.0 3 21,640
Mycobacterium avium complex 5.8 1 14,733
Pneumocystic pneumonia 13.0 7 8,214
Pneumonia 20.1 4 9,568
Tuberculosis 4.9 4 12,432
Toxoplasmic encephalitis 1.9 2 16,822
Wasting syndrome 22.8 1 4,072
Cryptococcal meningitis 1.2 1 11,354
Other 14.2 0 n.a.
Total 100 36 8,264
Occurrence of AIDS events and estimated costs (Euro price level 2006) as observed in the UMCG. For 14.2% of all AIDS events no event data was 
available in the UMCG due to the relatively small number of patients. These types are Cervical cancer, Cytomegalovirus Retinitis, Cytomegalovirus 
Other, Coccidiosis, HIV-Dementia, Histoplasmosis, Kaposi sarcoma, visceral, Salmonella sepsis, Cryptosporidium, Progressive multifocal 
leucoencephalopathy
UMCG: university medical center GroningenCost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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resulted in €51,600 and €40,700 per QALY for the dis-
count rate for costs, and €37,900 and €54,300 per QALY
for the discount rate for effects, respectively. The impact of
a 5% slower and faster disease progression on the iCER
was modest with €41,300 and €43,700 per QALY, respec-
tively.
Discussion
Our model generally shows that TPV/r versus CPI/r treat-
ment in heavily treatment experienced HIV infected
patients provides benefits regarding reductions in AIDS
events and corresponding QALY gains and life years
saved. This was achieved at a cost-effectiveness ratio of
crudely €40,000 per LYG or QALY.
Generally in the Netherlands drug interventions with an
iCER below €20,000 per LYG are certainly considered
cost-effective and are accepted for reimbursement [22]. In
particular in the field of last-resort treatments however –
including inpatient oncologic treatments and HIV treat-
ments – drugs with an iCER over €20,000 per LYG are
accepted. Various considerations underlie this: (i) in the
international context the Dutch cost-effectiveness thresh-
old at €20,000 is relatively low, compared to for example
to the generally accepted $50,000 per QALY for the
United States or £30,000 for the United Kingdom; and (ii)
recent discussion at Ministerial level have suggested to
raise the Dutch threshold up to €80,000. Our base-case
estimate for TPV/r may thus well be acceptable in the
Dutch context. Indeed, tipranavir was recommended for
reimbursement in the Netherlands by the Foundation for
Health Care Insurance in February 2006. In a budget
impact analysis, this institution estimated the additional
costs of treatment with TPV/r in the Netherlands to be
€905,000 €1,470,000 and €2,070,000 for the first, sec-
ond and third year respectively, assuming a number of
HIV patients on HAART in the Netherlands of 7747 and a
substitution of 30% within the patient population eligible
for TPV/r. The number of PI-experienced patients on sal-
vage treatment and eligible for TPV/r was estimated to be
no higher than 235 in the 3rd year [23].
Tornado diagram of the sensitivity analysis Figure 2
Tornado diagram of the sensitivity analysis. Tornado diagram of the univariate sensitivity analysis showing the impact of 
individual cost parameters on the iCER per QALY. Parameter values of 75% and 125% of the base-case value were evaluated 
and these values are shown on both sides of the bars. All parameters refer to costs and are expressed in Euro price level 2006. 
TPV/r tipranavir with ritonavir. CPI/r comparator protease inhibitor with ritonavir. HAART highly active antiretroviral therapy. 
iCER incremental cost effectiveness ratio. QALY quality adjusted life year.Cost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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In the context of the international health economic litera-
ture for treatment of HIV disease, cost-effectiveness results
vary significantly. These studies generally do however not
directly compare two antiretroviral components in the
context of HAART. In the UK, Miners et al. reported an
iCER of UK £17,698 per QALY in 2000 for adding an
unspecified PI to lamivudine and zidovudine [24]. Anis et
al. compared triple therapy to two dual regimens, report-
ing iCERs of Can $46,971 and Can $58,806 per LYG in
1997 for the stavudine- and zidovudine-based regimens,
respectively [25]. In the context of HAART, Simpson et al.
have evaluated lopinavir/ritonavir versus nelfinavir and
report an iCER per QALY of US $6,653 in 2002 using the
same model as was used for this study based on a different
clinical trial [16]. Caro et al. report efavirenz to be cost
saving when comparing efavirenz versus indinavir com-
bined with two NRTIs in 1998 [26].
We have used a Markov model to approximate the com-
plexity of sequential antiretroviral regimens that are typi-
cal for treatment of HAART experienced patients. In the
absence of transition probabilities for the Netherlands,
our study is limited by the fact that the health state transi-
tion probabilities were based on a clinical trial with pri-
marily non-Dutch participants and a large observational
cohort in the United States. Also, the AIDS event rate for
each health state was calculated from this cohort. How-
ever, transition probabilities and AIDS event rates found
comparable to those derived from a cohort of 3000 US
patients and 900 Dutch patients, published by Ghani and
colleagues [27]. Additionally, AIDS event cost data was
collected from a Dutch population of HIV infected
patients treated in the UMCG, whereas the majority of
HIV infected patients in the Netherlands are treated in
Amsterdam. We do however not expect major differences
between the Amsterdam and Groningen patient popula-
tions.
We did not specifically include the costs of adverse events
in this model because inclusion of such costs in this same
analysis for other countries (unpublished data) had
shown that this inclusion had a very minor effect on the
iCER. We note that our estimate for the cost of an AIDS
event of €8,264 is substantially lower than the $30,291
(€30,466 price level 2006) reported by Simpson et al. for
the United States in 2002 [16]. This difference can be par-
tially attributed to the 5-week cut-off after the date of the
AIDS-event used for the resource use data collection. Our
approach reflects a conservative approach, neglecting
chronic treatment or potential long-term complications of
which the direct relation with the event may be very
uncertain. Also, this model parameter has a very limited
effect on the iCER. Using the value reported by Simpson
et al. [16] our model projects an iCER of 39,000 €/QALY,
just slightly below our base-case estimate.
Conclusion
In conclusion, we estimated the iCER per QALY for TPV/r
compared to CPI/r to be €42,500 in treatment experi-
enced HIV-1 infected patients in the Netherlands. This
ratio may well be in range of what is acceptable and war-
rants reimbursement for new drug treatments in the Neth-
erlands, in particular in therapeutic areas as end-stage
oncology and HIV and other last-resort healthcare inter-
ventions.
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Appendix – Summary of the RESIST-2 trial and 
its 48-week results
The population of the randomized phase III efficacy and
safety trial RESIST-2 consisted of HIV-1 positive patients
in Europe and Latin America that have experienced previ-
ous treatment from all classes of antiretrovirals: Nucleo-
side Reverse Transcriptase Inhibitors, Non Nucleoside
Reverse Transcriptase Inhibitors and at least two protease
inhibitor based regimens for a period of minimum three
months. The trial was conducted over the period 2003–
2004. Patients had a viral load of >= 1000 with any CD4+
cell count, with at least one primary PI mutation. The
baseline mean and standard deviation (between brackets)
of CD4+ count was 219 (192) for the TPV/r arm and 217
(168) for the CPI/r arm. The overall aim of the study was
to investigate whether TPV demonstrates similar or better
efficacy and comparable safety as the drugs chosen in the
active control group. The endpoint was the proportion of
patients with a treatment response in terms of at least a 1
log10 viral load reduction.
All patients received an optimized standard of care regi-
men selected by their physician. Patient were randomized
to include in this regimen either TPV/r or a comparator PI/
r.
A total of 879 patients were randomized, with 863 being
evaluable. Kaplan-Meier estimates of time to treatment
failure indicated a significant difference in favor of TPV (p
< 0.0001). Treatment response after 48 weeks was higherCost Effectiveness and Resource Allocation 2007, 5:15 http://www.resource-allocation.com/content/5/1/15
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in the TPV group at 34% versus 15% in the active controls.
Many active controls (57%) changed the drug or discon-
tinued due to virologic failure (versus 18% in the TPV
group). In the different strata defined by comparator drug
(lopinavir, saquinavir and amprenavir) similar results
were seen. Also, CD4+ counts increased more for TPV
than for controls (26 cells/mm3 versus 1 cell/mm3), with
similar counts at baseline (219 and 217). Co-administra-
tion of enfuvirtide increased the proportion of patients
with a treatment response in both arms of the trial. The
researchers summarize that: "the results of this 48-week
interim summary show that the TPV regimen (in combi-
nation with other antiretroviral agents) was significantly
more effective than the comparator regimen (in combina-
tion with other antiretroviral agents) in postponing treat-
ment failure or achieving a treatment response in patients
who had previously received multiple antiretroviral ther-
apy". Benefits provided by the TPV regimen through 48
weeks were enhanced by co-administration of other active
antiretroviral agents, including enfuvirtide. Adverse
events (AEs) occurred more in the TPV arm of the trial
(88% vs. 78% of patients for all AEs). This resulted in dis-
continuation of study medication for 11% of TPV users
and 6% for comparator drugs. There were no differences
in overall serious AEs (both at 17%), however 3% of TPV
users had serious AEs considered related to study medica-
tion, against 0.5% for comparator drugs.
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